<DOC>
	<DOCNO>NCT00332852</DOCNO>
	<brief_summary>This prospective open-label one-arm phase III trial design evaluate safety efficacy letrozole 2.5 mg administer orally daily 24 month adjuvant therapy postmenopausal patient primary breast cancer . This trial recruit patient United States .</brief_summary>
	<brief_title>Letrozole Early Adjuvant Treatment Postmenopausal Patients With Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion : Compliant postmenopausal woman primary operable breast cancer complete surgery suitable endocrine treatment Nodal status negative positive Good Health status 02 ( Eastern Cooperative Oncology Group ) Estrogen and/or progesteronereceptor positive Adequate marrow , kidney liver function Exclusion criterion : Metastatic inflammatory breast cancer Patients previous concomitant cancer ( breast cancer ) within past 5 year EXCEPT adequately treat basal squamous cell skin cancer situ cancer cervix . Patients previous cancer must diseasefree least 5 year Patients uncontrolled , nonmalignant systemic cardiovascular , kidney , liver disease . Current/active dental problem include infection teeth jawbone , dental fixture trauma , current prior diagnosis osteonecrosis jaw , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery Patients primary overactive parathyroid Patients know hypersensitivity zoledronic acid bisphosphonates .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Postive breast cancer</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>disease free survival</keyword>
	<keyword>letrozole</keyword>
	<keyword>early adjuvant treatment</keyword>
	<keyword>primary hormone receptor</keyword>
</DOC>